Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis

Sandoz, a Novartis division and a global leader in biosimilars, announced the first patient enrolled in ROSALIA, an integrated Phase I/III clinical study for its proposed biosimilar denosumab.